# US 2010/0167325 A1 · Methods for detecting risk of fatal prostate cancer using serum calcium

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167325 A1
- Document ID: US20100167325A1
- Status: Published application
- Kind: A1
- Application number: 12/644,209
- Filed: 2009-12-22
- Published: 2010-07-01
- Earliest claimed: 2008-12-29
- Assignees: Wake Forest University Health Sciences
- Inventors: Gary G. Schwartz; Halcyon G. Skinner
- Web page: https://patentgrep.com/patent/US20100167325A1

## CPC

- G01N 33/84: involving inorganic compounds or pH
- G01N 27/00: Investigating or analysing materials by the use of electric, electrochemical, or magnetic means (G01N3/00 – G01N25/00 take precedence; measurement or testing of electric or magnetic variables or of electric or magnetic properties of materials G01R)
- G01N 33/57555: of the prostate
- G01J 3/42: Absorption spectrometry; Double beam spectrometry; Flicker spectrometry; Reflection spectrometry (beam switching arrangements G01J3/08)
- G01J 3/46: Measurement of colour; Colour measuring devices, e.g. colorimeters (measuring colour temperature G01J5/60)
- G01N 33/575: for cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G01J: MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY (light sources F21, H01J, H01K, H05B; investigating properties of materials by optical means G01N)

## Abstract

A method of screening for increased risk of fatal prostate cancer in a subject comprises providing a blood sample collected from the subject, and then detecting the presence or absence of an increased level of serum calcium in the sample. An increased level of serum calcium indicates the subject is at increased risk of fatal prostate cancer.

## Claims

### Claim 1

A method of screening for increased risk of fatal prostate cancer in a human male subject, comprising:
providing a blood sample collected from said subject; and
detecting the presence or absence of an increased level of serum calcium in said sample, an increased level of serum calcium indicating said subject is at increased risk of fatal prostate cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein said blood sample comprises whole blood, blood plasma, or blood serum.

### Claim 3 (depends on 1)

The method of claim 1, wherein said providing step comprises collecting a blood sample from said subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein said providing step comprises at least partially purifying said blood sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein said detecting step is a quantitative detecting step.

### Claim 6 (depends on 1)

The method of claim 1, wherein said serum calcium is ionized serum calcium, and wherein said detecting step is carried out by:
contacting said sample to an ion-selective electrode; and then
potentiometrically measuring ionized calcium in said sample through said electrode.

### Claim 7 (depends on 1)

The method of claim 1, wherein said serum calcium is total serum calcium, and said detecting step is carried out by absorption spectrometry.

### Claim 8 (depends on 1)

The method of claim 1, wherein said serum calcium is total serum calcium, and said detecting step is carried out by:
atomizing said sample in an atomic absorption spectrophotometer to provide an atomized sample; then
illuminating said atomized sample with light in said atomic absorption spectrophotometer; then
detecting light from said atomized sample with a detector; and then
determining the amount of total serum calcium in said sample from said detected light by atomic absorption spectrophotometry.

### Claim 9 (depends on 1)

The method of claim 1, wherein said serum calcium is total serum calcium, and said detecting step is a colorimetric detecting step.

### Claim 10 (depends on 1)

The method of claim 1, wherein said serum calcium is total serum calcium, and said detecting step is carried out by:
combining said sample with a metallochromic indicator dye that binds calcium to form a complex; and then
colorimetrically measuring the formation of said complex to determine the amount of calcium in said sample.

### Claim 11 (depends on 10)

The method of claim 10, wherein said metallochromic indicator dye is an arsenazo dye or orthocresolphthalein complexone.

### Claim 12 (depends on 1)

The method of claim 1, wherein said serum calcium is total serum calcium, and said detecting step is a fluorescent detecting step.

### Claim 13 (depends on 1)

The method of claim 1, wherein said serum calcium is total serum calcium, and said detecting step is carried out by:
combining said sample with a chelating agent that binds calcium and forms a fluorescent complex therewith; and then
detecting fluorescence from said sample to determine the amount of calcium in said sample.

### Claim 14 (depends on 13)

The method of claim 13, wherein said chelating agent is EDTA or EGTA.

### Claim 15 (depends on 1)

The method of claim 1, wherein said serum calcium is total serum calcium, and said detecting step is carried out by enzymatic assay.

### Claim 16 (depends on 1)

The method of claim 1, wherein said serum calcium is total serum calcium, and said detecting step is carried out by:
combining said sample with an enzyme that is activated or inhibited by calcium: and then
detecting the activation or inhibition of said enzyme to determine the amount of calcium in said sample.

### Claim 17 (depends on 1)

The method of claim 1, wherein said enzyme is alpha amylase, phospholipase D, or urea amidolyase.

### Claim 18 (depends on 1)

The method of claim 1, wherein said calcium is total serum calcium, and said detecting step comprises detecting a total serum calcium level greater than 2.3 mmol/L to provide an indication of increased risk of fatal prostate cancer in said subject.

### Claim 19 (depends on 1)

The method of claim 1, wherein said calcium is ionized serum calcium, and said detecting step comprises detecting an ionized serum calcium level greater than 1.2 mmol/L to provide an indication of increased risk of fatal prostate cancer in said subject.
